Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018;14(9):e1007679. doi:10.1371/journal.pgen.1007679
Chen PJ, Hussmann JA, Yan J, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021;184(22):5635-5652.e29. doi:10.1016/j.cell.2021.09.018
Jabbari K, Bobbili DR, Lal D, et al. Rare gene deletions in genetic generalized and Rolandic epilepsies. PLoS One. 2018;13(8):e0202022. doi:10.1371/journal.pone.0202022
Hacken ET, Wu CJ. Understanding CLL biology through mouse models of human genetics. Blood. 2021;138(25):2621-2631. doi:10.1182/blood.2021011993
Adeegbe DO, Liu S, Hattersley MM, et al. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in -Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res. 2018;6(10):1234-1245. doi:10.1158/2326-6066.CIR-18-0077
Krishnan Y, Rees HA, Rossitto CP, et al. Green fluorescent proteins engineered for cartilage-targeted drug delivery: Insights for transport into highly charged avascular tissues. Biomaterials. 2018;183:218-233. doi:10.1016/j.biomaterials.2018.08.050
Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018;128(10):4441-4453. doi:10.1172/JCI121924
Guemez-Gamboa A, Çağlayan AO, Stanley V, et al. Loss of Protocadherin-12 Leads to Diencephalic-Mesencephalic Junction Dysplasia Syndrome. Ann Neurol. 2018;84(5):638-647. doi:10.1002/ana.25327
Rahme GJ, Gaskell E, Bernstein BE. GABPβ1L Wakes Up TERT. Cancer Cell. 2018;34(3):358-360. doi:10.1016/j.ccell.2018.08.011
Bellmunt J, Lalani AKA, Jacobus S, et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018;119(6):707-712. doi:10.1038/s41416-018-0261-0